Tabberer, Maggie
Williamson, Nicola
Tatlock, Sophi
Gater, Adam
Grimes, Rebecca
Akinseye, Chika
Neil, David
Mahon-Smith, Aoife
Nelsen, Linda http://orcid.org/0000-0002-3929-4064
Funding for this research was provided by:
GSK (GSK)
Article History
Received: 16 March 2023
Accepted: 10 March 2024
First Online: 20 April 2024
Declarations
:
: <b>Stage 1</b>: Concept elicitation interviews, ethical approval was obtained from the Copernicus Independent Review Board and the study was conducted in accordance with the Declaration of Helsinki. When required, ethics approval was also obtained from sites.<b>Stage 2</b>: The protocol was approved by all relevant Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs), and the study was registered at ClinicalTrials.gov (NCT03359473). The study was conducted in accordance with Good Clinical Practice and all applicable regulatory requirements, as well as the guiding principles of the Declaration of Helsinki.
: Not applicable.
: CA and LN are employees of and hold stocks in GSK. MT and DN were employees of GSK at the time of the study. MT holds stocks in GSK. NW, AG, AM-S and ST are employees of Adelphi Values. RG was an employee of Adelphi Values at the time of the study. Adelphi Values received funding from GSK to conduct this study but not payment for manuscript development.